NUVASIVE, INC. (NASDAQ:NUVA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

NUVASIVE, INC. (NASDAQ:NUVA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

Effective March23, 2018, the Board of Directors of NuVasive, Inc. (the “Company”) designated Rajesh J. Asarpota as the Company’s principal accounting officer for purposes of the rules and regulations of the Securities and Exchange Commission. Since September 2017, Mr.Asarpota has served at the Company’s Executive Vice President and Chief Financial Officer, and in such role was designated as the Company’s principal financial officer. Mr.Asarpota will now serve as the Company’s principal financial officer and principal accounting officer. Mr.Asarpota assumed accounting responsibilities from Jereme Sylvain, who has served as the principal accounting officer since August 2016. Mr.Asarpota’s current title and compensation shall not change as a result of these additional accounting responsibilities.


About NUVASIVE, INC. (NASDAQ:NUVA)

Nuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.

An ad to help with our costs